Jurisdictions · Singapore
Singapore is the market that moved its own deadlines, and it moved most of them.
On 25 August 2025, ACRA and SGX RegCo extended the timelines for almost every climate reporting requirement they had set eighteen months earlier. Large non-listed companies went from FY2026 to FY2030. Assurance for those companies went from FY2027 to FY2032. The stated reason was the uncertain global economic environment and feedback about differing levels of readiness.
That makes Singapore the most useful jurisdiction to study if you are trying to decide how much weight to put on a published timetable, and the most dangerous to plan from second-hand material. A great deal of what is written about Singapore still carries the original dates.
Before and after
What changed in August 2025.
Two requirements survived untouched: Scope 1 and Scope 2 emissions for all listed issuers, and the wider climate disclosures for Straits Times Index constituents, both from FY2025. Everything else moved, and the further down the size ladder an obligation sat, the further it moved.
Scroll sideways →
| Requirement | Who | Was | Now |
|---|---|---|---|
| Scope 1 and 2 emissions | All listed issuers | FY2025 | FY2025 |
| Wider climate disclosures | STI constituents | FY2025 | FY2025 |
| Scope 3 emissions | STI constituents | FY2025 | FY2026 |
| Wider climate disclosures | Listed, non-STI, market cap S$1bn+ | FY2026 | FY2028 |
| Wider climate disclosures | Listed, non-STI, under S$1bn | FY2027 | FY2030 |
| Limited assurance, Scope 1 and 2 | Listed issuers | FY2026 | FY2029 |
| Climate disclosures incl. Scope 1 and 2 | Large non-listed companies | FY2026 | FY2030 |
| Limited assurance, Scope 1 and 2 | Large non-listed companies | FY2027 | FY2032 |
Both columns from ACRA's announcement of the extended timelines and its current requirements timeline. Large non-listed companies are those meeting both tests: annual revenue of S$1 billion or more and total assets of S$500 million or more, unless an exemption applies.
Scoping
Singapore sorts by index membership, not by size tests.
Australia and Malaysia both scope by characteristics of the entity: two of three size tests, or an emissions registration, or a revenue threshold. Singapore's listed regime sorts by where you sit in the market. The top tier is membership of the Straits Times Index. The second is market capitalisation of S$1 billion or more. The third is everyone else on the exchange.
This has a consequence worth planning around. Index membership and market capitalisation are not stable, and they are not within your control. ACRA fixed the measurement for the middle tier at 30 June 2025, which removes the uncertainty for that cohort, but the underlying design ties obligations to market position rather than to the scale of the business.
The non-listed test is more familiar: revenue of S$1 billion or more and total assets of S$500 million or more, and unusually both must be met rather than two of three. That is a narrow gate, and it is one reason the non-listed population caught by this regime is far smaller than Malaysia's or Australia's.
The planning problem
A deferral is not the same as a reprieve, and treating it as one is how companies lose four years.
When a regulator moves a date out by four years, the rational response looks obvious and is usually wrong. The obligation did not go away. It was restated, by the same two bodies, with a new date attached and a reason given that was about capability rather than about doubt over the destination.
There is also a quieter asymmetry in the revised schedule. Reporting moved, and assurance moved further. A listed issuer now reports Scope 1 and 2 from FY2025 but is not assured on them until FY2029, which is four unassured cycles. Those four years produce the comparatives and the methodology history that the first assurance engagement will examine. Nothing about the deferral makes those years less consequential; it just removes the person who would have told you they were going wrong.
The practical read is that the deferral changed when you are marked, not when the work counts. The data you generate in an unassured year is the data an assurer will trace back to, and a methodology chosen casually in FY2026 is a methodology you will be explaining in FY2029.
One thing that did not move
Scope 1 and Scope 2 for all listed issuers has been in force since FY2025 throughout, and STI constituents have had the wider climate disclosures from FY2025 as well. If you are an SGX-listed issuer, the earliest obligations were never deferred, and the extensions apply to what comes next rather than to what is already due.
Divergences
Three ways Singapore asks for less than the standard does.
Singapore describes its requirements as ISSB-based rather than as an adoption of the standards. That wording is doing real work: the requirements are built into the SGX Listing Rules and, for non-listed companies, into a separate obligation, rather than IFRS S1 and IFRS S2 being given legal force as written.
Compare with Australia, which legislated the standard and mandates reasonable assurance across the whole report from 2030, and Malaysia, which adopts IFRS S1 and S2 in full on a staged basis. Three neighbours, three quite different answers.
S$1bn+
smaller
non-listed
Where to start
Use the deferral rather than spending it.
Singapore has handed most of its reporting population something the other markets in the region did not get: several unassured cycles with a known end date. The companies that come out of this well will be the ones that treat FY2026 to FY2028 as the period in which the emissions boundary gets fixed, the methodology gets written down and the review trail starts existing, rather than the period before the work starts.
The cheapest thing to do now is also the most valuable later: make each figure traceable to a source document and record who approved it. That is what the FY2029 engagement will ask for, and it cannot be reconstructed afterwards.
Score your evidence position →Six minutes, no signup. Or check your cohort and first period, read what IFRS S2 requires, or see how every other market is sequencing this.